Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27812477 | 0.98 | CD44 (0.33) | CD44MCL1 | |
| SCHEMBL826511 | 0.92 | CD44 (0.39) | CD44MCL1CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL23529793 | 0.82 | HTT (0.35) | — | |
| SCHEMBL31619918 | 0.82 | HTT (0.35) | — | |
| SCHEMBL1578248 | 0.82 | AHR (0.37) | — | |
| SCHEMBL28681881 | 0.77 | ABL1 (0.33) | — | |
| SCHEMBL13751191 | 0.75 | ACHE (0.37) | SLC6A2SLC6A4SLC6A3PTGS2 | |
| SCHEMBL9847915 | 0.74 | MEN1 (0.35) | CYP2D6SLC6A4SLC6A3 | |
| SCHEMBL31727021 | 0.74 | ACHE (0.38) | — | |
| SCHEMBL10525774 | 0.73 | PTGS2 (0.35) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343763-B2 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120149742-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-14 | — | — | US | disclosed |
| US-8143297-B2 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110098328-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-28 | — | — | US | disclosed |
| EP-2307412-A2 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2011-04-13 | — | — | EP | disclosed |
| US-7846954-B2 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-07 | — | — | US | disclosed |
| WO-2010002956-A2 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-07 | — | — | WO | disclosed |
| US-20100004300-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149742-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | TRPV1, KCNJ2, KCNN3 | CD44 3285/4885MCL1 2400/4885CYP2D6 1652/4885 |
| US-20100004300-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | TRPV1, KCNJ2, KCNN3 | CD44 3285/4885MCL1 2400/4885CYP2D6 1652/4885 |
| US-20110098328-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | TRPV1, KCNJ2, KCNN3 | CD44 3285/4885MCL1 2400/4885CYP2D6 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.